Copper‑free click chemistry reagents for bioconjugation: DBCO, BCN and tetrazine selection guide

Copper‑free click reagents DBCO, BCN and tetrazine each offer distinct kinetics, stability and functional‑group compatibility. DBCO provides reliable SPAAC with azides (k≈10^2 M⁻¹ s⁻¹), BCN is smaller but slower, while tetrazine–TCO ligation is the fastest (k≈10^4‑10^5 M⁻¹ s⁻¹) but requires strained alkene partners. Choose based on reaction speed, steric constraints and biological context.

What are the main differences between DBCO, BCN and tetrazine reagents for copper‑free bioconjugation?

• Chemical class – DBCO (dibenzocyclooctyne) and BCN (bicyclononyne) are cyclooctyne derivatives used in strain‑promoted azide‑alkyne cycloaddition (SPAAC). Tetrazine reagents belong to the inverse‑electron‑demand Diels‑Alder (IEDDA) family and react with strained alkenes such as trans‑cyclooctene (TCO).
• Reaction kinetics – Reported second‑order rate constants in aqueous buffer at 25 °C are roughly 1 × 10^2 M⁻¹ s⁻¹ for DBCO‑azide, 1 × 10^1 M⁻¹ s⁻¹ for BCN‑azide, and 1 × 10^4‑1 × 10^5 M⁻¹ s⁻¹ for tetrazine‑TCO. The IEDDA reaction is therefore 10‑1000‑fold faster.
• Size and steric impact – BCN is the smallest cyclooctyne (≈9 Å) and often causes less perturbation to protein surfaces than DBCO (≈12 Å). Tetrazine tags are typically <8 Å, but the TCO partner adds bulk.
• Stability – DBCO and BCN are stable to air and moisture for months when stored at –20 °C under inert atmosphere. Tetrazines can undergo hydrolysis; most commercial tetrazine‑NHS esters retain >80 % activity after 6 months at –20 °C, but repeated freeze‑thaw cycles accelerate degradation.
• Functional‑group compatibility – SPAAC tolerates most nucleophiles and does not require catalyst, making it suitable for live‑cell labelling. IEDDA tolerates a broader pH range (5‑8) but can be quenched by excess thiols if the tetrazine is not sterically protected.

When should I choose DBCO over BCN for strain‑promoted azide‑alkyne cycloaddition?

• Protein‑size constraints – If the azide is positioned near a tightly packed active site, the smaller BCN may access the site more readily. For surface‑exposed azides, DBCO’s larger ring does not impede conjugation.
• Reaction time – In typical bioconjugation (1‑10 µM azide, 10‑100 µM cyclooctyne), DBCO reaches >90 % conversion within 30 min, whereas BCN may require 1‑2 h under identical conditions.
• Solubility – DBCO is often supplied as a PEG‑linked derivative (e.g., DBCO‑PEG4‑NHS) to improve aqueous solubility. BCN derivatives are more lipophilic; they may need up to 5 % DMSO to stay in solution, which can affect sensitive cells.
• Cost and availability – DBCO reagents are generally 1.5‑2 × more expensive than BCN, but the higher reaction rate can offset the cost in high‑throughput workflows.
• Application example – For antibody‑drug conjugates where the azide is introduced on a lysine side chain, DBCO‑PEG4‑NHS is preferred to ensure rapid, quantitative labelling without organic co‑solvent.

How does the tetrazine–trans‑cyclooctene (TCO) ligation compare with SPAAC in terms of rate and stability?

| Parameter | SPAAC (DBCO/BCN‑azide) | Tetrazine‑TCO (IEDDA) | |-----------|-----------------------|----------------------| | k (M⁻¹ s⁻¹) | 10¹‑10² (BCN) – 10² (DBCO) | 10⁴‑10⁵ | | Typical concentration for >90 % conversion | 10‑100 µM cyclooctyne, 1‑10 µM azide, 30 min – 2 h | 1‑10 µM tetrazine, 0.1‑1 µM TCO, 1‑5 min | | Aqueous stability (25 °C, pH 7.4) | >6 months (dry, –20 °C) | Tetrazine: 3‑6 months; TCO: 1‑2 months (prone to isomerisation) | | Sensitivity to nucleophiles | Low | Moderate – free thiols can reduce tetrazine, especially unprotected variants | | In‑vivo suitability | Proven for live‑cell surface labelling; limited by slower kinetics | | In‑vivo suitability | Ideal for rapid PET‑probe labelling and pre‑targeted therapy due to sub‑minute kinetics |

The IEDDA reaction’s speed makes it the method of choice when labelling must be completed within seconds to minutes, such as in pre‑targeted radio‑imaging. However, the need for a strained alkene partner (TCO) adds a synthetic step and may introduce isomerisation that reduces reactivity over time.

What practical considerations affect the handling and storage of copper‑free click reagents?

1. Temperature – Store all reagents at –20 °C in sealed amber vials. DBCO and BCN tolerate brief exposure to 4 °C, but tetrazines should be kept frozen until use.
2. Moisture – Even though SPAAC reagents are moisture‑stable, water can promote hydrolysis of NHS‑activated tetrazine esters. Desiccants in the storage container are advisable.
3. Solvent choice – For immediate use, dissolve DBCO‑PEG4‑NHS in anhydrous DMSO (≤10 % v/v final in aqueous buffer). BCN derivatives often require 5‑10 % DMSO. Tetrazine‑NHS is typically supplied in DMF; limit DMF to ≤2 % v/v in biological assays to avoid cytotoxicity.
4. Light sensitivity – Tetrazines are light‑sensitive; protect from UV and store in amber glass. DBCO and BCN are less sensitive but benefit from reduced light exposure.
5. Purity verification – Prior to critical experiments, confirm reagent integrity by HPLC or LC‑MS. A typical purity threshold is ≥95 % for commercial batches; any degradation peaks >5 % warrant fresh aliquot preparation.

Molekula provides a range of PEG‑linked DBCO and BCN reagents with documented stability data, as well as tetrazine‑NHS esters stored under nitrogen to minimise hydrolysis.

Which reagent is most suitable for in‑vivo labelling of proteins or cells?

• Surface‑labelling of live cells – DBCO‑PEG4‑NHS is widely used because it reacts rapidly at 37 °C, tolerates serum proteins, and does not require a second strained partner. Typical protocol: 10 µM DBCO‑PEG4‑NHS for 30 min, wash, then add azide‑fluorophore (5‑10 µM) for another 15 min.
• Rapid pre‑targeted imaging – Tetrazine‑TCO is preferred when the biological window is minutes. An example is a two‑step PET‑probe: first inject TCO‑modified antibody, wait 24 h for tumour accumulation, then inject ^18F‑tetrazine (≤1 µM) which ligates within 5 min.
• Intracellular labelling – BCN‑PEG4‑NHS can cross cell membranes more readily than DBCO due to lower hydrophobicity, making it useful for cytosolic protein labelling after electroporation or microinjection.
• Stability in circulation – DBCO and BCN are relatively inert to serum proteins, whereas tetrazine can be reduced by circulating glutathione (≈5 mM). Shielded tetrazines (e.g., di‑aryl) improve plasma stability but increase synthesis cost.

In summary, for routine live‑cell surface labelling DBCO is the most robust choice; for ultra‑fast in‑vivo imaging tetrazine‑TCO offers unmatched kinetics, provided the TCO‑modified biomolecule is stable in circulation.

Frequently asked questions

Q1: Can I mix DBCO and tetrazine reagents in the same reaction? A: Yes, but avoid simultaneous addition to the same azide or TCO site, as cross‑reactivity is negligible. Sequential labelling is recommended to prevent steric hindrance.

Q2: Is copper‑free click compatible with nucleic‑acid conjugation? A: SPAAC works well with azide‑modified oligonucleotides; BCN is preferred when the oligo is sensitive to organic co‑solvents. Tetrazine‑TCO can be used for rapid labelling of strained‑alkene‑modified nucleic acids, but the TCO must be introduced chemically.

Q3: How do I quantify the degree of labelling? A: Use UV‑Vis spectroscopy for chromophoric tags, or LC‑MS to determine the mass shift. For protein conjugates, a combination of SDS‑PAGE (Coomassie) and densitometry provides an approximate labelling ratio.

Q4: What safety precautions are required? A: All reagents are low‑toxicity, but handle DMSO, DMF and DMF‑containing stock solutions in a fume hood. Wear nitrile gloves and eye protection; tetrazines can be irritant and should be kept away from strong reducing agents.